Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Meryl Comer, UsAgainstAlzheimer's and Meryl Comer. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Meryl Comer, UsAgainstAlzheimer's and Meryl Comer or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Ep 98: The Future of Alzheimer's Trials: Bringing Cutting-Edge Research to Every Community - John Dwyer, CEO of The Global Alzheimer's Platform

16:52
 
Share
 

Manage episode 520005772 series 41856
Content provided by Meryl Comer, UsAgainstAlzheimer's and Meryl Comer. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Meryl Comer, UsAgainstAlzheimer's and Meryl Comer or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

BrainStorm wants to hear from you! Send us a text.

The quest to speed up clinical trials is personal for John Dwyer, CEO of the Global Alzheimer's Platform (GAP). A long-time UsA2 advocate, he’s been motivated by the generations of family members lost to Alzheimer's and Parkinson's disease. Dwyer shares with BrainStorm host Meryl Comer the critical challenges of NIH funding cuts by the Trump Administration, forcing many trial sites to shut down at a time of new FDA-cleared blood tests for early diagnosis. Dwyer highlights GAP's innovations in improving the participant experience through streamlining visits, personalized feedback, and bringing mobile trials directly to small communities. This must listen episode reinforces clinical trial participation as a valuable care option while advancing research for millions affected by Alzheimer's and related dementias.

This episode of BrainStorm is sponsored by Johnson & Johnson

Support the show

  continue reading

60 episodes

Artwork
iconShare
 
Manage episode 520005772 series 41856
Content provided by Meryl Comer, UsAgainstAlzheimer's and Meryl Comer. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Meryl Comer, UsAgainstAlzheimer's and Meryl Comer or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

BrainStorm wants to hear from you! Send us a text.

The quest to speed up clinical trials is personal for John Dwyer, CEO of the Global Alzheimer's Platform (GAP). A long-time UsA2 advocate, he’s been motivated by the generations of family members lost to Alzheimer's and Parkinson's disease. Dwyer shares with BrainStorm host Meryl Comer the critical challenges of NIH funding cuts by the Trump Administration, forcing many trial sites to shut down at a time of new FDA-cleared blood tests for early diagnosis. Dwyer highlights GAP's innovations in improving the participant experience through streamlining visits, personalized feedback, and bringing mobile trials directly to small communities. This must listen episode reinforces clinical trial participation as a valuable care option while advancing research for millions affected by Alzheimer's and related dementias.

This episode of BrainStorm is sponsored by Johnson & Johnson

Support the show

  continue reading

60 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play